Although Ads with E1b deletions or E1a regulated by cancer selective promoters have achieved some success in human clinical trials, the efficacy of oncolytic Ad virotherapy overall has been disappointing [8,29,31,38,39]. The gene discussed is DHTKD1; the disease is cancer.